Lantheus Medical Imaging : DEFINITY®
| DEFINITY®, is based on perflutren lipid microsphere, to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border |
Company Web Site:DEFINITY® |
The FDA has recently granted a class labeling change to Definity® based on the Prescribing Information revisions modifing DEFINITY®’s benefit/risk assessment.
To compare the Oct 2007 to the April 2008 visit the FDA Label & Approval history page devoted to Definity®.
| Ultrasound Contrast Agents | |
| Approved | In Development |
| Bracco: SonoVue® | Acusphere, Inc™: magify™ |
| Bristol-Myers Squibb: DEFINITY® | AION Diagnostics, Inc: modified porous silicon |
| GE: OPTISON™ | Targeson, LLC: Targestar™ |
| IMACOR: Imagent | ImaRx Therapeutics, Inc: SonoLysis™ |
| POINT Biomedical: CARDIOsphere™ | |
Please Note:
The trademarks, copyrights, company, product , & organization names shown on this site are provided for reference purposes. Each is owned by the respective companies & organizations. Unless stated otherwise, none are affiliated with EchoChief.com or its publisher, Insonoart, Inc.
The web sites of Insonoart, Inc are not intended to provide medical advice, nor is any information here a substitute for professional healthcare. Consult your doctor or other healthcare provider for information about your diagnosis, treatment or condition.
